Loading
Loading
Research Overview
C-terminal fragment of HGH (residues 176–191); selectively stimulates lipolysis and inhibits lipogenesis via β-adrenergic signalling without activating IGF-1 pathways or promoting insulin resistance. Functionally overlaps with AOD-9604.
HGH Fragment 176-191 is a C-terminal fragment of human growth hormone studied for its selective lipolytic properties. By isolating the portion of the HGH molecule responsible for fat metabolism, researchers have investigated whether the compound can stimulate lipolysis without the insulin resistance, IGF-1 elevation, and water retention associated with full-length HGH administration.
Preclinical research in animal models has examined the compound's effects on adipose tissue mobilisation, β-adrenergic receptor pathways, and lipogenesis suppression. Its short half-life of approximately 30 minutes and subcutaneous route of administration (typically fasted, before cardio) define the research administration protocols used in most studies.
The compound is closely related to AOD-9604 — both isolate the same HGH C-terminal region involved in fat metabolism, and the two peptides are sometimes described as functionally overlapping in research literature. Clinical development for obesity was discontinued after failing to demonstrate sufficient efficacy in Phase 2–3 trials.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, hgh fragment 176-191 has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
HGH Fragment 176-191 research is most relevant to protocols examining:
Targeted fat loss research without IGF-1 or insulin effects
β-adrenergic lipolysis mechanism studies
Researchers comparing HGH Fragment 176-191 vs AOD-9604 mechanistically
Body composition research in GH-axis contexts
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~30 minutes). Review data, confirm baseline recovery before any repeat protocol.
C-terminal fragment of HGH (residues 176–191); selectively stimulates lipolysis and inhibits lipogenesis via β-adrenergic signalling without activating IGF-1 pathways or promoting insulin resistance. Functionally overlaps with AOD-9604.
| Parameter | Value |
|---|---|
| Dose range | 250–500 mcg/dose, 1–2× daily |
| Schedule | Fasted, before cardio |
| Route | Subcutaneous, Intranasal |
| Half-life | ~30 minutes |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
